NEW YORK (GenomeWeb News) — PolyOrg said today that it has licensed from the Copenhagen Inventor Group the right to make and sell PNA monomers worldwide.
PNAs are oligonucleotide analogs in which the sugar-phosphate backbone of DNA is substituted by amino-ethyl-glycine backbone. They hybridize strongly to complementary DNA or RNA but are not degraded by nucleases or proteases, the company said, and they are useful for molecular biology and diagnostics applications and antisense and anti-gene therapies.
Under the non-exclusive license, PolyOrg will initially offer Fmoc/Bhoc protected monomers, which are are compatible with "several" commercially automated DNA/Peptide/PNA synthesizers, the company said.
Financial terms of the agreement were not released.